Nuwellis to Host Webinar Discussing ULTRA-Peds Registry Results and Aquadex Performance in Critically Ill Pediatric Patients

Nuwellis to Host Webinar Discussing ULTRA-Peds Registry Results and Aquadex Performance in Critically Ill Pediatric Patients
Published byZeest Media
November 19, 2026

MINNEAPOLIS, Nov. 19, 2026 (ZM NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will host a live educational webinar, “ULTRA-Peds Results Analysis and Discussion,” on December 1, 2026, at 1:00 p.m. Eastern Time. The event will feature a panel of lead and contributing authors of the multicenter study titled “Kidney Support in Infants and Children using Aquadex: Findings from the ULTRA-Peds Registry,” which was recently accepted for publication in Pediatric Nephrology, to discuss key findings and their implications for pediatric fluid management.

“Managing fluid overload in critically ill children presents unique challenges, particularly given the complexity of treating smaller and more vulnerable patients,” said Mike McCormick, President and Chief Executive Officer of Nuwellis. “The ULTRA-Peds Registry provides valuable real-world insights into the use of Aquadex in pediatric care, and we believe it is important to bring the clinical community together to discuss these findings. This webinar reflects our ongoing commitment to advancing clinical education, fostering collaboration, and helping healthcare professionals make informed decisions when managing complex fluid conditions.”

The ULTRA-Peds Registry was designed to collect both clinical and machine-level data from pediatric patients receiving Aquadex therapy. In addition to evaluating patient outcomes, the study examined technical performance, including circuit duration, blood flow rates, and treatment interruptions. Researchers found that approximately 86% of cases with complete data lasted their planned treatment duration, providing additional insights into the system’s performance in critically ill pediatric patients. Most circuits that ended early did so because of vascular access problems or clotting, challenges commonly encountered in this patient population.

The webinar will be moderated by Stuart Goldstein, MD, FAAP, FNKF, Pediatric Nephrologist and Director of the Center for Acute Care Nephrology at Cincinnati Children’s Hospital. During the session, the study’s investigators will review the registry findings, discuss the clinical and technical considerations associated with ultrafiltration therapy in pediatric patients, and share perspectives on how the results may inform future treatment approaches.

Webinar Details:

  • Title: ULTRA-Peds Results Analysis and Discussion
  • Date: Tuesday, December 1, 2026
  • Time: 1:00 p.m. Eastern Time
  • Format: Live virtual discussion with lead and contributing study authors
  • CME Credit: None
  • Registration: Register Here

Healthcare professionals, researchers, and other interested participants are encouraged to register in advance.

About Aquadex
The Aquadex SmartFlow® System is currently indicated for the continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ strategy includes expanding its portfolio through internally developed technologies and strategic commercial partnerships that broaden its presence across acute and chronic critical care. For more information, visit www.nuwellis.com.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
CORE IR
ir@nuwellis.com

Media Contact:
CORE PR
media@nuwellis.com

Publication Partner: ZM Newswire – Powered By Zeest Media

This press release is provided by the issuer. The statements and opinions expressed are those of the author and do not necessarily reflect the views of Zeest Media.

© 2026 Zeest Media. All rights reserved.

WhatsApp